Mary Schaheen | President
Prevail Partners Llc

I am a strategic investor that is focused on clinical stage biotech companies that are positioned to achieve a value inflection with a successful clinical trial. Prevail has invested in 50 private and public companies, which have done about $5 billion in licensing deals and had numerous successful IPOs.